Successfully on a course for growth
In 1965, Dr Fritz Wörwag founded the City pharmacy in Stuttgart-Zuffenhausen. Just 6 years later, he decided to develop and sell his own pharmaceutical products and founded WÖRWAG Pharma. By introducing focussed and high quality medications, he finally laid a further foundation stone in the successful history of this family run enterprise from Swabia.
With the market launch of the successful product Magnerot Classic (in 1981) as well as the fat soluble Benfotiamine (in 1985) there soon began to emerge a clearly differentiated market position with a unique profile: WÖRWAG Pharma proved its core competence in the treatment of diabetes and its accompanying disorders and, in addition, established itself as a specialist in the area of biofactors.
1992 was a decisive year for WÖRWAG Pharma: With Thiogamma, another successful medication for effective treatment of diabetic polyneuropathies entered the market. An important step was also the introduction of generics as well as a large number of new products in the biofactor area.
WÖRWAG Pharma goes internationally
The capture of new markets in the Eastern German regions was followed in 1993 by international expansion. With much energy many international activities were established. In 1993, the first office opened in Hungary. Within 10 years there were a further 12 new locations as in Russia, Romania, Bulgaria and many other Eastern European countries.
Today WÖRWAG Pharma is growing its presence in Asia and Latin America with great success. To date, more than 700 employees are working in 30 sales offices across the world.
These highly significant years for the development of WÖRWAG Pharma were followed in 2000 by the handover to another generation. Monika Wörwag and Dr. Marcus Wörwag took over leadership of the business. In 2008, Roland Spleiss joined them as an additional Managing Director.
Since then, the core competences and the focus of the company have been further expanded. As an internationally active family run enterprise, WÖRWAG Pharma is still focussed on future world-wide growth.
Our continuously growing turnover enables us to look into the future with great optimism